ACET - NASDAQ

Adicet Bio, Inc.

ACET·NASDAQ

$8.15

+4.1%

HealthcareBiotechnology

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$76.18M

EPS-16.9500

P/E Ratio-0.48

Earnings Date08/06/2026

192.35M

Assets

-13%

3Y-42.0%

5Y+25.0%

10Y-64.0%

33.15M

Total Liabilities

-1%

3Y-14.0%

5Y-25.0%

10Y-86.0%

159.21M

Total Equity

-15%

3Y-46.0%

5Y+45.0%

10Y-48.0%

Adicet Bio, Inc. Funding & Solvency Profile

ACET · NASDAQ

Current Assets

Cash & Cash Equivalents38.92M

Net Receivables342.00K

Inventory0.00

Other Current Assets2.05M

Total Current Assets161 M

Non-Current Assets

Property, Plant & Equipment28.48M

Goodwill & Intangible Assets0.00

Long-Term Investments2.87M

Other Non-Current Assets76.00K

Total Non-Current Assets31 M

Total Assets

192.35M

Financial Health Analysis

Current Ratio

7.47x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.21x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

139 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

84% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Adicet Bio, Inc. Balance Sheet

ACET • NASDAQ

Adicet Bio, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Jun 2017	Jun 2016	Jun 2015	Jun 2014	Jun 2013	Jun 2012	Jun 2011	Jun 2010	Jun 2009	Jun 2008
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	38.9M	56.5M	159.7M	257.7M	277.5M	84.3M	10.6M	7M	53.3M	66.8M	34M	42.9M	33.2M	24.9M	28.7M	30.9M	57.8M	46.5M
Short-Term Investments	119.6M	119.8M	0.0	0.0	0.0	10.3M	51.8M	101M	2M	881K	3.4M	746K	2.1M	1.5M	943K	335K	541K	548K
Cash & Short-Term Investments	158.5M	176.3M	159.7M	257.7M	277.5M	94.6M	62.4M	108M	53.3M	67.7M	37.4M	43.6M	35.4M	26.4M	29.6M	31.2M	58.3M	47.1M
Net Receivables	342K	0.0	0.0	435K	214K	2.7M	935K	0.0	0.0	167.6M	161.5M	122.7M	90.1M	74.7M	83.7M	74.7M	0.0	0.0
Accounts Receivables	0.0	0.0	0.0	435K	185K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	342K	0.0	0.0	0.0	29K	2.7M	935K	0.0	0.0	167.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	672K	0.0	136.4M	98.1M	95.6M	100.7M	83.8M	84.7M	77.4M	74.9M	54.4M	71.1M
Prepaids	0.0	3.4M	2.1M	2.6M	4.7M	2.6M	672K	923K	792K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Assets	2.1M	474K	457K	336K	2K	363K	-493K	15K	84K	19.2M	15.8M	9.3M	9M	6.2M	7.8M	14.8M	58.9M	75.6M
Total Current Assets	160.9M	180.1M	162.3M	261M	282.4M	100.3M	64.2M	109.5M	54.2M	352.7M	310.3M	276.4M	218.3M	192M	198.6M	195.6M	171.6M	193.8M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	28.5M	36.8M	44.2M	49M	35M	25.9M	2.1M	321K	39K	10M	10.5M	11.6M	11.4M	11.7M	12.1M	6.9M	4.2M	4.3M
Goodwill	0.0	0.0	0.0	19.5M	19.5M	20.1M	0.0	0.0	237M	67.9M	67.9M	66.5M	33.5M	33.5M	33.6M	1.7M	1.9M	2M
Intangible Assets	0.0	0.0	0.0	0.0	0.0	1.2M	0.0	0.0	285.1M	79.1M	79M	88M	40.8M	45.3M	50.7M	12.4M	11.5M	5.4M
Goodwill & Intangible Assets	0.0	0.0	0.0	19.5M	19.5M	21.3M	0.0	0.0	522.1M	146.9M	146.9M	154.5M	74.4M	78.7M	84.3M	14.1M	13.4M	7.4M
Long-Term Investments	2.9M	0.0	0.0	0.0	0.0	4.5M	10.6M	84K	-541.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	19.5M	18.1M	10M	11.6M	8.1M	4.7M	0.0	0.0	0.0	0.0
Other Non-Current Assets	76K	3.3M	822K	1.2M	2M	1.8M	4.7M	0.0	929K	13.1M	12.2M	14M	11.3M	12.1M	0.0	0.0	0.0	0.0
Total Non-Current Assets	31.4M	40.1M	45M	69.7M	56.5M	53.5M	17.4M	405K	968K	188.1M	179.5M	191.6M	105.1M	107.3M	96.4M	21M	17.6M	11.7M
Total Assets	192.4M	220.2M	207.3M	330.7M	338.9M	153.8M	81.6M	109.9M	55.2M	540.8M	489.8M	468M	323.4M	299.3M	295M	216.6M	189.3M	205.5M
LIABILITIES
CURRENT LIABILITIES
Total Payables	4.7M	4.8M	2.6M	4.4M	3.3M	1.6M	1.1M	538K	1.5M	0.0	55M	48.7M	39.2M	42M	44.6M	40M	25.1M	43.5M
Accounts Payable	4.7M	4.8M	2.6M	4.4M	3.3M	1.6M	1.1M	538K	1.5M	0.0	55M	48.7M	39.2M	42M	44.6M	40M	25.1M	43.5M
Other Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-55M	-48.7M	-39.2M	-42M	-44.6M	-40M	-25.1M	-43.5M
Accrued Expenses	0.0	4.3M	6.5M	7.1M	2.7M	3.8M	1.4M	1.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Short Term Debt	0.0	0.0	0.0	0.0	0.0	1.2M	0.0	0.0	14.5M	197K	10.2M	8.3M	11.7M	6.7M	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	3.2M	3.1M	3.2M	2.5M	1.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	64K	2.1M	0.0	6.4M	4M	800K	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	4.8M	14M	11M	0.0	238K	3.2M	2.1M	490K	701K	58K	747K	1.9M	1.6M	1.8M
Other Current Liabilities	13.6M	7.1M	6.9M	5.7M	4M	1.9M	1.5M	4M	-10.7M	49.4M	57.8M	61M	38.3M	24.9M	37.8M	32.8M	20.2M	19.8M
Total Current Liabilities	21.5M	19.4M	19.3M	19.7M	16.3M	22.5M	14.9M	5.7M	5.5M	98.9M	125M	118.5M	89.9M	73.6M	83.2M	74.6M	46.9M	65M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1M	339.2M	118.6M	100M	97.2M	20.4M	39.1M	6.2M	33.6M	20.7M	19.9M
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	10.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	125K	-114.1M	0.0	7.3M	9.1M	66K	6K	6K	8K	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	62K	116K	130K	114K	115K	980K	116.2M	-3.1M	-346.5M	6.3M	7.5M	11.6M	13.4M	12.9M	0.0	0.0	0.0	0.0
Total Non-Current Liabilities	11.6M	14.2M	17.8M	18.6M	19.5M	21.5M	127.1M	19K	408M	134.1M	107.6M	108.8M	33.8M	52M	6.2M	33.6M	20.7M	19.9M
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-408M	3.4M	3M	7.1M	5.1M	5.6M	61.4M	-16M	-3.8M	-3.1M
Capital Lease Obligations	14.7M	17.2M	20.9M	21M	20.9M	20.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	33.1M	33.6M	37.1M	38.4M	35.8M	44M	142M	5.7M	5.5M	236.3M	235.6M	234.4M	128.8M	131.3M	150.8M	92.2M	63.9M	81.8M
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	129.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	116M	38.1M	81.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Common Stock	10K	8K	4K	4K	4K	2K	4K	3K	1K	296K	292K	288K	278K	269K	266K	256K	256K	256K
Additional Paid-In Capital	773.8M	684.5M	550.9M	530.4M	471.4M	216.1M	9.3M	8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Retained Earnings	-614.7M	-497.9M	-380.8M	-238.1M	-168.3M	-106.3M	-69.6M	-71.4M	-33.8M	194.8M	167.2M	140.8M	118.6M	102.3M	90.7M	87M	85.5M	81.8M
Accumulated Other Comprehensive Income/Loss	102K	16K	0.0	0.0	0.0	24K	23K	-41K	-5.1M	-6.3M	-7.1M	5.4M	2.9M	1.3M	7.7M	953K	7.5M	13.1M
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	129.6M	7M	115.7M	93.8M	87.2M	72.8M	64.1M	62.1M	51.5M	48.3M	45.3M
Total Stockholders' Equity	159.2M	186.6M	170.2M	292.3M	303.1M	109.8M	-60.4M	104.2M	49.7M	304.4M	254.2M	233.6M	194.6M	168M	160.8M	139.6M	141.6M	140.4M
Total Equity	159.2M	186.6M	170.2M	292.3M	303.1M	109.8M	-60.4M	104.2M	49.7M	304.4M	254.2M	233.6M	194.6M	168M	160.8M	139.6M	141.6M	140.4M
SUMMARY
Total Liabilities & Equity	192.4M	220.2M	207.3M	330.7M	338.9M	153.8M	81.6M	109.9M	55.2M	540.8M	489.8M	468M	323.4M	299.3M	295M	216.6M	189.3M	205.5M
Total Investments	122.5M	119.8M	0.0	0.0	0.0	14.8M	62.4M	101.1M	2M	881K	3.4M	746K	2.1M	1.5M	943K	335K	541K	548K
Total Debt	14.7M	17.2M	20.9M	21M	20.9M	21.6M	114.1M	3.1M	353.7M	118.8M	110.2M	105.5M	32.1M	45.8M	55M	33.6M	20.7M	19.9M
Net Debt	-24.2M	-39.3M	-138.8M	-236.6M	-256.6M	-62.7M	103.5M	-3.9M	300.3M	52M	76.1M	62.6M	-1.2M	20.9M	26.3M	2.7M	-37M	-26.6M
Shares Outstanding	91,682,318	91,682,318	91,682,318	91,682,318	91,682,318	91,682,318	91,682,318	91,682,318	91,682,318	91,682,318	91,682,318	91,682,318	91,682,318	91,682,318	91,682,318	91,682,318	91,682,318	91,682,318

SEC Filings

ACET - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-K/A 10-K/A 2025 FY (Amended) FY	May 20, 2026	December 31, 2025	2025	View Filing
10-Q 10-Q 2026 Q1 Q1	May 13, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 13, 2026	May 13, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 29, 2026	April 29, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 28, 2026	April 27, 2026	2026	View Filing
S-3 S-3 N/A	March 12, 2026	March 12, 2026		View Filing
10-K 10-K 2025 FY FY	March 12, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 12, 2026	March 12, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 07, 2026	January 07, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 29, 2025	December 26, 2025	2025	View Filing

Showing 1 to 10 of 204 filings

Related Guides

Blog Categories

Continue your ACET research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.